Viral Safety (ICH Q5A)
ICH Q5A is the viral-safety cornerstone for biotechnology products derived from cell lines of human or animal origin. Because these products cannot be terminally sterilized and their raw materials and cell substrates can carry endogenous or adventitious viruses, safety is built on three complementary pillars: selecting and testing source materials, testing at appropriate production steps, and validating the process's capacity to clear virus. The recently revised version extends the framework explicitly to newer modalities.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 22 LINKSICH Q5A builds viral safety for cell-line biotech products on three pillars — source and cell-substrate testing, in-process testing, and validated viral clearance by spiking studies — since these products cannot be terminally sterilized.
06 · QUALITY MATURITY — VIRAL SAFETY (ICH Q5A), REACTIVE TO ADAPTIVE
Viral safety rests on end-product testing alone, with no clearance validation and thin raw-material control.
A cell-banking and testing scheme exists, but clearance claims lack orthogonality or a representative small-scale model.
All three pillars are in place: qualified cell banks, in-process testing, and validated, orthogonal viral-clearance studies.
Clearance margins and raw-material risk are monitored; process changes trigger re-evaluation of clearance before implementation.
Viral safety is engineered across the platform, with clearance orthogonality and modern detection (e.g. NGS) designed into the process.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 3
Derived from the 3 standards SPEQ maps to this subject, across 2 regulatory bodies: EMA, ICH.
RECORDS & OBJECTIVE EVIDENCE
- A qualified two-tier master and working cell bank tested for endogenous and adventitious viruses
- In-process viral testing (e.g. of unprocessed bulk harvest)
- Viral-clearance spiking studies at qualified small scale with orthogonal, mechanistically distinct steps
- Control or elimination of animal-derived raw materials
- Change-control records re-evaluating clearance after resin, buffer, membrane, or scale changes
COMMON INSPECTION FINDINGS
- Viral safety relying on testing alone without validated clearance
- Two claimed clearance steps sharing the same mechanism, not truly orthogonal
- A small-scale clearance model not shown to represent manufacturing
- Animal-derived raw materials without adequate viral control
- Process changes to resins or scale not reassessed for viral clearance
Why viral safety needs its own framework
Biotech products grown in mammalian, insect or human cell lines carry a risk that traditional chemical drugs do not: the biological source material can harbor viruses — endogenous retroviruses built into the genome of the cell line, or adventitious agents introduced through raw materials such as serum, media components or the cell bank itself. These products cannot be heat-sterilized without destroying the protein, so viral safety must be engineered into the source, the testing scheme and the purification process rather than added at the end.
ICH Q5A(R2) is the current revision and notably broadens the scope beyond classical recombinant proteins and monoclonal antibodies toward a wider range of biotechnology-derived products and modern platforms. It works alongside EU GMP Annex 2 for biological medicinal products and ICH Q11 for drug-substance development.
Pillar one and two: source control and testing
The first pillar is selecting, testing and characterizing the cell substrate and raw materials so that the starting point is defined and screened. This means a qualified two-tier cell-banking system — a master cell bank and a working cell bank — extensively tested for endogenous and adventitious viruses, plus control of animal-derived raw materials (or their elimination in favor of chemically defined media). Knowing exactly what viral burden could be present is the precondition for designing the rest of the safety case.
The second pillar is testing at appropriate stages of production — for example, unprocessed bulk harvest — to detect virus that may be present before purification. These tests confirm that the process is operating within its validated viral-burden assumptions and act as a monitoring layer. But because no test can rule out every possible agent at the sensitivity required, testing alone is never sufficient, which is why the third pillar exists.
Pillar three: validated viral clearance
The core of Q5A is demonstrating that the purification process actively removes and inactivates virus. This is done through spiking studies: known quantities of model viruses are deliberately added to scaled-down process intermediates, and the log reduction achieved by each clearance step (chromatography, low-pH hold, solvent/detergent treatment, nanofiltration) is measured. The steps must be mechanistically distinct so their clearance can be summed into a total log-reduction value that provides a large safety margin over the estimated input.
The studies must use relevant and model viruses chosen to challenge the process across enveloped/non-enveloped and physicochemical diversity, be performed at qualified small scale that represents manufacturing, and account for orthogonality so that no two claimed steps rely on the same clearance mechanism. SPEQ synthesis: the credibility of a viral-clearance claim rests on the small-scale model's representativeness and on genuine orthogonality — two chromatography steps with the same mechanism do not both count.
Lifecycle, changes and newer modalities
Viral clearance is validated for a defined process, so changes to unit operations, resins, buffers, membranes or scale can invalidate prior clearance claims and require re-evaluation under change control. The revised Q5A also engages with continuous and intensified processing and with the analytical advances (such as next-generation sequencing for adventitious-agent detection) that have matured since the original guideline, and it addresses how the framework applies to certain newer product classes.
For advanced modalities — viral vectors and some cell-based products — the framework interacts with product-specific considerations, because for a viral-vector product the "virus" is the drug, which changes how clearance and testing are framed. Practitioners must read Q5A(R2) together with modality-specific guidance rather than assuming the classical monoclonal-antibody paradigm transfers unchanged.
FREQUENTLY ASKED
What are the three pillars of ICH Q5A viral safety?
Selecting and testing source materials and cell substrates; testing at appropriate production stages such as unprocessed bulk harvest; and validating the process's capacity to remove and inactivate virus through spiking (clearance) studies. The three are complementary because no single one is sufficient on its own.
Why can't viral testing alone assure safety?
Because no test can detect every possible viral agent at the required sensitivity, and some agents may be unknown or present below detection limits. Testing confirms the process is operating within its assumptions, but the primary safety assurance comes from validated clearance that provides a large log-reduction margin over the estimated input burden.
What does ICH Q5A(R2) add?
The revision broadens scope toward a wider range of biotechnology products and modern platforms, engages with continuous/intensified processing, and reflects newer analytical methods such as next-generation sequencing for adventitious-agent detection. It should be read with modality-specific guidance for advanced products.
Do clearance claims survive process changes?
Not automatically. Viral clearance is validated for a specific process; changes to resins, buffers, membranes, unit operations or scale can invalidate prior claims and must be assessed under change control, often requiring repeat spiking studies at the qualified small scale.